Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 403

Results For "Inc"

6656 News Found

Solvay partners with Ostium in single-use surgical instruments material recycling
Sustainability | November 09, 2022

Solvay partners with Ostium in single-use surgical instruments material recycling

Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.


Zydus receives USFDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets
Drug Approval | November 09, 2022

Zydus receives USFDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets

The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India


Ami Organics Q2 FY23 revenue up 20.2%; Profit up 9%
News | November 08, 2022

Ami Organics Q2 FY23 revenue up 20.2%; Profit up 9%

The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23


Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr
News | November 08, 2022

Vinati Organics consolidated Q2FY23 PAT up 43% at Rs. 116 Cr

The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.


SeQuent Scientific to acquire 100% stake in Tineta Pharma
News | November 08, 2022

SeQuent Scientific to acquire 100% stake in Tineta Pharma

The acquisition is for an enterprise value of Rs. 218 crores


Astec LifeSciences plan Capex of Rs. 300 - 350 Cr
News | November 08, 2022

Astec LifeSciences plan Capex of Rs. 300 - 350 Cr

R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab


Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%
News | November 07, 2022

Tatva Chintan Q2 FY23 revenue down 27%; Net profit down 78%

Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%


Lupin receives tentative approval from USFDA for Drospirenone Tablets
Drug Approval | November 07, 2022

Lupin receives tentative approval from USFDA for Drospirenone Tablets

Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US